Organic Letters, volume 6, issue 17, pages 2901-2904

Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans

Anne-Marie Faucher ¹

Murray D. Bailey ¹

Pierre L Beaulieu ¹

Christian Brochu ¹

Jean-Simon Duceppe ¹

Jean-Marie Ferland ¹

Elise Ghiro ¹

Vida Gorys ¹

Ted Halmos ¹

Stephen H Kawai ¹

Martin Poirier ¹

Bruno Simoneau ¹

CHARLES A. COLE ¹

Montse Llinas-Brunet ¹

Show full list: 14 authors

Hide authors affiliations Show authors affiliations: 1 affiliation

Chemistry Department, Boehringer Ingelheim (Canada) Ltd., Research and Development, 2100 Cunard Street, Laval, (Québec) Canada H7S 2G5 |

Publication type: Journal Article

Publication date: 2004-07-21

American Chemical Society (ACS)

Journal: Organic Letters

scimago Q1

SJR: 1.245

CiteScore: 9.3

Impact factor: 4.9

ISSN: 15237060, 15237052

DOI: 10.1021/ol0489907

Copy DOI

PubMed ID: 15330643

Organic Chemistry

Biochemistry

Physical and Theoretical Chemistry

Abstract

The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclinical pharmacological evaluation.

Found 0

Clear filter

By date By citations

Found 0

Clear filter

By date By citations

Top-30

Journals

	1 2 3 4 5 6 7 8
Organic Process Research and Development	Organic Process Research and Development, 8, 8.16% Organic Process Research and Development 8 publications, 8.16%
Journal of Organic Chemistry	Journal of Organic Chemistry, 5, 5.1% Journal of Organic Chemistry 5 publications, 5.1%
Chemical Reviews	Chemical Reviews, 5, 5.1% Chemical Reviews 5 publications, 5.1%
Organic Letters	Organic Letters, 5, 5.1% Organic Letters 5 publications, 5.1%
Journal of Organometallic Chemistry	Journal of Organometallic Chemistry, 4, 4.08% Journal of Organometallic Chemistry 4 publications, 4.08%
Journal of Medicinal Chemistry	Journal of Medicinal Chemistry, 4, 4.08% Journal of Medicinal Chemistry 4 publications, 4.08%
Bioorganic and Medicinal Chemistry	Bioorganic and Medicinal Chemistry, 3, 3.06% Bioorganic and Medicinal Chemistry 3 publications, 3.06%
Bioorganic and Medicinal Chemistry Letters	Bioorganic and Medicinal Chemistry Letters, 3, 3.06% Bioorganic and Medicinal Chemistry Letters 3 publications, 3.06%
Antimicrobial Agents and Chemotherapy	Antimicrobial Agents and Chemotherapy, 3, 3.06% Antimicrobial Agents and Chemotherapy 3 publications, 3.06%
Tetrahedron	Tetrahedron, 2, 2.04% Tetrahedron 2 publications, 2.04%
Angewandte Chemie - International Edition	Angewandte Chemie - International Edition, 2, 2.04% Angewandte Chemie - International Edition 2 publications, 2.04%
Angewandte Chemie	Angewandte Chemie, 2, 2.04% Angewandte Chemie 2 publications, 2.04%
European Journal of Organic Chemistry	European Journal of Organic Chemistry, 2, 2.04% European Journal of Organic Chemistry 2 publications, 2.04%
Chemistry - A European Journal	Chemistry - A European Journal, 2, 2.04% Chemistry - A European Journal 2 publications, 2.04%
Advanced Synthesis and Catalysis	Advanced Synthesis and Catalysis, 2, 2.04% Advanced Synthesis and Catalysis 2 publications, 2.04%
Topics in Heterocyclic Chemistry	Topics in Heterocyclic Chemistry, 2, 2.04% Topics in Heterocyclic Chemistry 2 publications, 2.04%
Beilstein Journal of Organic Chemistry	Beilstein Journal of Organic Chemistry, 1, 1.02% Beilstein Journal of Organic Chemistry 1 publication, 1.02%
Future Virology	Future Virology, 1, 1.02% Future Virology 1 publication, 1.02%
Molecules	Molecules, 1, 1.02% Molecules 1 publication, 1.02%
Applied Biochemistry and Biotechnology	Applied Biochemistry and Biotechnology, 1, 1.02% Applied Biochemistry and Biotechnology 1 publication, 1.02%
Journal of Gastroenterology	Journal of Gastroenterology, 1, 1.02% Journal of Gastroenterology 1 publication, 1.02%
Acta Pharmacologica Sinica	Acta Pharmacologica Sinica, 1, 1.02% Acta Pharmacologica Sinica 1 publication, 1.02%
Science	Science, 1, 1.02% Science 1 publication, 1.02%
Bioorganic Chemistry	Bioorganic Chemistry, 1, 1.02% Bioorganic Chemistry 1 publication, 1.02%
Antiviral Research	Antiviral Research, 1, 1.02% Antiviral Research 1 publication, 1.02%
Journal of Hepatology	Journal of Hepatology, 1, 1.02% Journal of Hepatology 1 publication, 1.02%
Journal of Biological Chemistry	Journal of Biological Chemistry, 1, 1.02% Journal of Biological Chemistry 1 publication, 1.02%
Drug Discovery Today	Drug Discovery Today, 1, 1.02% Drug Discovery Today 1 publication, 1.02%
Coordination Chemistry Reviews	Coordination Chemistry Reviews, 1, 1.02% Coordination Chemistry Reviews 1 publication, 1.02%
	1 2 3 4 5 6 7 8

Publishers

	5 10 15 20 25 30
American Chemical Society (ACS)	American Chemical Society (ACS), 28, 28.57% American Chemical Society (ACS) 28 publications, 28.57%
Wiley	Wiley, 26, 26.53% Wiley 26 publications, 26.53%
Elsevier	Elsevier, 22, 22.45% Elsevier 22 publications, 22.45%
Springer Nature	Springer Nature, 7, 7.14% Springer Nature 7 publications, 7.14%
American Society for Microbiology	American Society for Microbiology, 3, 3.06% American Society for Microbiology 3 publications, 3.06%
MDPI	MDPI, 2, 2.04% MDPI 2 publications, 2.04%
Beilstein-Institut	Beilstein-Institut, 1, 1.02% Beilstein-Institut 1 publication, 1.02%
Taylor & Francis	Taylor & Francis, 1, 1.02% Taylor & Francis 1 publication, 1.02%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 1, 1.02% American Association for the Advancement of Science (AAAS) 1 publication, 1.02%
American Society for Biochemistry and Molecular Biology	American Society for Biochemistry and Molecular Biology, 1, 1.02% American Society for Biochemistry and Molecular Biology 1 publication, 1.02%
Georg Thieme Verlag KG	Georg Thieme Verlag KG, 1, 1.02% Georg Thieme Verlag KG 1 publication, 1.02%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 1.02% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 1 publication, 1.02%
	5 10 15 20 25 30

We do not take into account publications without a DOI.
Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

10 Field Citation Ratio

1.49 Relative Citation Ratio

Cite this

GOST |

Cite this

GOST Copy

Faucher A. et al. Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans // Organic Letters. 2004. Vol. 6. No. 17. pp. 2901-2904.

GOST all authors (up to 50) Copy

Faucher A., Bailey M. D., Beaulieu P. L., Brochu C., Duceppe J., Ferland J., Ghiro E., Gorys V., Halmos T., Kawai S. H., Poirier M., Simoneau B., COLE C., Llinas-Brunet M. Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans // Organic Letters. 2004. Vol. 6. No. 17. pp. 2901-2904.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1021/ol0489907

UR - https://doi.org/10.1021/ol0489907

TI - Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans

T2 - Organic Letters

AU - Faucher, Anne-Marie

AU - Bailey, Murray D.

AU - Beaulieu, Pierre L

AU - Brochu, Christian

AU - Duceppe, Jean-Simon

AU - Ferland, Jean-Marie

AU - Ghiro, Elise

AU - Gorys, Vida

AU - Halmos, Ted

AU - Kawai, Stephen H

AU - Poirier, Martin

AU - Simoneau, Bruno

AU - COLE, CHARLES A.

AU - Llinas-Brunet, Montse

PY - 2004

DA - 2004/07/21

PB - American Chemical Society (ACS)

SP - 2901-2904

IS - 17

VL - 6

PMID - 15330643

SN - 1523-7060

SN - 1523-7052

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2004_Faucher,

author = {Anne-Marie Faucher and Murray D. Bailey and Pierre L Beaulieu and Christian Brochu and Jean-Simon Duceppe and Jean-Marie Ferland and Elise Ghiro and Vida Gorys and Ted Halmos and Stephen H Kawai and Martin Poirier and Bruno Simoneau and CHARLES A. COLE and Montse Llinas-Brunet},

title = {Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans},

journal = {Organic Letters},

year = {2004},

volume = {6},

publisher = {American Chemical Society (ACS)},

month = {jul},

url = {https://doi.org/10.1021/ol0489907},

number = {17},

pages = {2901--2904},

doi = {10.1021/ol0489907}

}

MLA

Cite this

MLA Copy

Faucher, Anne-Marie, et al. “Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans.” Organic Letters, vol. 6, no. 17, Jul. 2004, pp. 2901-2904. https://doi.org/10.1021/ol0489907.

Found error?

Message

Support chat

Publisher

American Chemical Society (ACS)

Journal

Organic Letters

scimago Q1

SJR

1.245

CiteScore

9.3

Impact factor

4.9

ISSN

15237060 (Print)

15237052 (Electronic)